Characteristics and outcomes of gemcitabine-associated pulmonary hypertension.
Fiche publication
Date publication
mai 2024
Journal
ERJ open research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNIAUD Philippe, Dr BELTRAMO Guillaume
Tous les auteurs :
Mouillot P, Favrolt N, Khouri C, Grandvuillemin A, Chaumais MC, Schenesse D, Seferian A, Jais X, Savale L, Beltramo G, Sitbon O, Cracowski JL, Humbert M, Georges M, Bonniaud P, Montani D
Lien Pubmed
Résumé
Despite its known cardiac and lung toxicities, the chemotherapy drug gemcitabine has only rarely been associated with pulmonary hypertension (PH), and the underlying mechanism remains unclear. The objective of the present study was to assess the association between gemcitabine and PH.
Référence
ERJ Open Res. 2024 05;10(3):